425: Palvella Therapeutics Secures $2.6 Million FDA Grant for Phase 3 Trial of QTORIN in Microcystic Lymphatic Malformations

Palvella Therapeutics receives a grant of up to $2.6 million from the FDA to support its Phase 3 SELVA study of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations.

Summary

• Pieris Pharmaceuticals reported that Palvella Therapeutics received a grant of up to $2.6 million from the FDA's Office of Orphan Products Development.
• The grant will support Palvella's ongoing Phase 3 SELVA trial of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations.
• The Phase 3 trial is a single-arm, baseline-controlled study.
• Palvella's QTORIN rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs, and Fast Track Designation for venous malformations.
• The merger between Pieris and Palvella, announced on July 23, 2024, is still subject to customary closing conditions.

Sentiment

Score: 8

Explanation: The announcement of the FDA grant is a positive development for Palvella, indicating external validation of their research and development efforts and providing financial support for a key clinical trial. This is likely to be viewed favorably by investors.

Positives

• The FDA grant validates the scientific rationale and unmet medical need for treating microcystic lymphatic malformations.
• QTORIN rapamycin has the potential to become the first FDA-approved therapy for microcystic LMs.
• The FDA's Orphan Products Grants Program has a successful track record, having funded clinical trials that facilitated the approval of over 85 products.
• QTORIN rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs, and Fast Track Designation for venous malformations.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The proposed merger between Pieris and Palvella is subject to customary closing conditions and may not be completed.
• QTORIN rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.

Future Outlook

Palvella is focused on developing and commercializing novel therapies for rare genetic skin diseases, with QTORIN rapamycin as its lead product candidate.

Management Comments

• Wes Kaupinen, Founder and Chief Executive Officer of Palvella, stated that the grant underscores the high unmet medical need in microcystic LMs and QTORIN rapamycin's potential to be the first approved therapy.

Industry Context

The announcement highlights the ongoing efforts to develop treatments for rare diseases and the role of FDA grants in supporting these initiatives.

Comparison to Industry Standards

• The FDA Orphan Products Grants Program is a well-established initiative that supports the development of treatments for rare diseases.
• The program has funded clinical trials that have led to the approval of more than 85 products, demonstrating its significant impact on the rare disease landscape.
• Companies like BioMarin Pharmaceutical and Sarepta Therapeutics have also benefited from similar programs, bringing innovative therapies to market for rare genetic disorders.

Stakeholder Impact

• The grant and ongoing clinical trial could lead to the development of a new treatment option for patients with microcystic lymphatic malformations.
• The successful development and commercialization of QTORIN rapamycin could benefit Palvella's shareholders.
• The merger between Pieris and Palvella could create synergies and enhance the combined company's pipeline.

Next Steps

• Palvella will continue the Phase 3 SELVA trial of QTORIN rapamycin.
• Pieris intends to file relevant materials with the SEC, including a registration statement on Form S-4, in connection with the proposed transaction.

Key Dates